Evidence map›Paper›PMID 36540407›Full record

ArticleRSC advances2022

Design, and synthesis of selectively anticancer 4-cyanophenyl substituted thiazol-2-ylhydrazones.

Hasnain Mehmood, Mustapha Musa, Simon Woodward, Md Shahadat Hossan, Tracey D Bradshaw, Muhammad Haroon, Andrew Nortcliffe, Tashfeen Akhtar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Design, Synthesis, andACS omega · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hasnain MehmoodDepartment of Chemistry, Mirpur University of Science and Technology (MUST) 10250-Mirpur (AJK) Pakistan tashfeenchem@must.edu.pk.
Mustapha MusaGSK Carbon Neutral Laboratories for Sustainable Chemistry, University of Nottingham Triumph Road Nottingham NG7 2TU UK.
Simon WoodwardGSK Carbon Neutral Laboratories for Sustainable Chemistry, University of Nottingham Triumph Road Nottingham NG7 2TU UK.ORCID https://orcid.org/0000-0001-8539-6232
Md Shahadat HossanSchool of Pharmacy, University of Nottingham University Park Nottingham NG7 2RD UK.
Tracey D BradshawSchool of Pharmacy, University of Nottingham University Park Nottingham NG7 2RD UK.ORCID https://orcid.org/0000-0001-8451-5092
Muhammad HaroonDepartment of Chemistry, Mirpur University of Science and Technology (MUST) 10250-Mirpur (AJK) Pakistan tashfeenchem@must.edu.pk.
Andrew NortcliffeSchool of Chemistry, University of Nottingham University Park Nottingham NG7 2RD UK.ORCID https://orcid.org/0000-0002-3371-390X
Tashfeen AkhtarDepartment of Chemistry, Mirpur University of Science and Technology (MUST) 10250-Mirpur (AJK) Pakistan tashfeenchem@must.edu.pk.ORCID https://orcid.org/0000-0002-4815-0687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclization of substituted thiosemicarbazones with α-bromo-4-cyanoacetophenone allows rapid single-step sustainable syntheses of 4-cyanophenyl-2-hydrazinylthiazoles libraries (30 examples, 66-79%). All show anticancer efficacy against HCT-116 and MCF-7 carcinoma cell lines with the majority being more active than cisplatin positive controls. The compounds 2-(2-(2-hydroxy-3-methylbenzylidene)hydrazinyl)-4-(4-cyanophenyl)thiazole (3f) and 2-(2-((pentafluorophenyl)methylene)-hydrazinyl)-4-(4-cyanophenyl)thiazole (3a') show optimal GI

Identifiers

PMID36540407
PMCPMC9704493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.